Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04428333
Title	Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Acronym	INDUCE-4
Recruitment	Terminated
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	GlaxoSmithKline
Indications	oropharynx cancer laryngeal squamous cell carcinoma head and neck squamous cell carcinoma hypopharynx cancer oral cavity cancer
Therapies	Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + GSK3359609 + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + GSK3359609 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| ROU \| POL \| ITA \| IRL \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG